Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $2.9 million.

  • ARS Pharmaceuticals' Other Non-Current Assets rose 67400.53% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 67400.53%. This contributed to the annual value of $3.1 million for FY2024, which is 38808.78% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Other Non-Current Assets stood at $2.9 million, which was up 67400.53% from $3.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Other Non-Current Assets high stood at $3.2 million for Q3 2023, and its period low was $23000.0 during Q4 2021.
  • In the last 5 years, ARS Pharmaceuticals' Other Non-Current Assets had a median value of $638000.0 in 2023 and averaged $1.6 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' Other Non-Current Assets skyrocketed by 1277391.3% in 2022 and then plummeted by 8811.85% in 2024.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Other Non-Current Assets stood at $23000.0 in 2021, then soared by 12773.91% to $3.0 million in 2022, then tumbled by 78.45% to $638000.0 in 2023, then skyrocketed by 388.09% to $3.1 million in 2024, then fell by 6.29% to $2.9 million in 2025.
  • Its Other Non-Current Assets was $2.9 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.1 million in Q1 2025.